SCHEMBL651369

SCHEMBL651369

CCCCn1c(-c2ccccc2)nc(-c2ccc(F)c(F)c2)c1CN(Cc1cccc(OCC)c1)Cc1ccc2c(c1)OCO2

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.54
GNRHR P30968 4/20 0.38
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CTSL P07711 2/20 0.37
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
F2R P25116 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
MAPT P10636 1/20 0.36
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649243 0.94 C5AR1 (0.60) C5AR1LMNASMN1; SMN2L3MBTL1PPARG
SCHEMBL650956 0.93 C5AR1 (0.58) C5AR1GNRHRLMNASMN1; SMN2L3MBTL1
SCHEMBL652971 0.93 C5AR1 (0.56) C5AR1GNRHRLMNASMN1; SMN2L3MBTL1
SCHEMBL648344 0.93 C5AR1 (0.63) C5AR1GNRHRLMNASMN1; SMN2L3MBTL1
SCHEMBL649030 0.92 C5AR1 (0.60) C5AR1GNRHRLMNASMN1; SMN2L3MBTL1
SCHEMBL651150 0.92 C5AR1 (0.61) C5AR1LMNASMN1; SMN2L3MBTL1PPARG
SCHEMBL650609 0.92 C5AR1 (0.63) C5AR1GNRHRLMNASMN1; SMN2L3MBTL1
SCHEMBL649488 0.91 C5AR1 (0.56) C5AR1LMNASMN1; SMN2L3MBTL1PPARG
SCHEMBL651379 0.91 C5AR1 (0.56) C5AR1GNRHRLMNASMN1; SMN2L3MBTL1
SCHEMBL1912830 0.91 C5AR1 (0.58) C5AR1GNRHRLMNASMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490343-A1 NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS Neurogen Corporation (US) 2004-12-29 EP claimed
US-20040116424-A1 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION 2004-06-17 US claimed
WO-2003082829-A1 NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2003-10-09 WO claimed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed